Original Articles
EXPRESSION OF IL-6, sgp130, IL-8 AND THEIR RECEPTORS IN ACUTE PROMYELOCYTIC LEUKEMIA DURING ALL-TRANS RETINOIC ACID INDUCTION TREATMENT
Abstract
Objective: To evaluate the expression and its clinical significance of interleukin 6 (IL-6), soluble glyeoprotein 130 (sgp130), inlerleukin 8 (IL-8) and type A interlenkin 8 receptor (IL-8RA) in acute promyelocytic leukemia (APL) patients during all-trans retinoic acid (ATRA) induction treatment.
Methods: Plasma and bone marrow mononuclear cell (MNC) culture supernatant IL-6, sgpl30, IL-8 concentration of 18 cases with APL were kinetically measured in vivo and in vitro (ELISA). Bone marrow MNC IL-8RA was measured by flow eytometry after being cultured with ATRA (10-6mmol/L).
Results: Plasma IL-6, sgp130, IL-8 levels were higher than normal (P<0.05), IL-6, sgpt30 levels correlated with white blood cell (WBC) counts (P<0.05) while IL-8 levels correlated with body temperature (P<0.05) at initial diagnosis. Afler 72-hour incubation with ATRA, concentration of IL-6 of bone marrow MNC culture supernatant did not change, that of sgp130 mildly decreased, and IL-8 significantly decreased while the positive rate of IL-8RA on bone marrow MNC increased. During ATRA treatment, plasma IL-6 changes were correlated with WBC counts. Peak levels of IL-6 and WBC were lower in patients who received intermittent therapy than those who received continuous therapy. Plasma IL-6 and IL-8 were increased when complicated with infection and IL-8 seemed more sensitive.
Conclusion: Plasma IL-6, sgpl30, IL-8 levels may reflect patients' responsiveness to ATRA treatment, and could be used to predict hyperleukocytosis and intercurrent infection. ATRA induces APL cell differentiation possibly via sgpl30 signal transducer chain. Measurement of sgp130 had certain meaning to prognosis.
Methods: Plasma and bone marrow mononuclear cell (MNC) culture supernatant IL-6, sgpl30, IL-8 concentration of 18 cases with APL were kinetically measured in vivo and in vitro (ELISA). Bone marrow MNC IL-8RA was measured by flow eytometry after being cultured with ATRA (10-6mmol/L).
Results: Plasma IL-6, sgp130, IL-8 levels were higher than normal (P<0.05), IL-6, sgpt30 levels correlated with white blood cell (WBC) counts (P<0.05) while IL-8 levels correlated with body temperature (P<0.05) at initial diagnosis. Afler 72-hour incubation with ATRA, concentration of IL-6 of bone marrow MNC culture supernatant did not change, that of sgp130 mildly decreased, and IL-8 significantly decreased while the positive rate of IL-8RA on bone marrow MNC increased. During ATRA treatment, plasma IL-6 changes were correlated with WBC counts. Peak levels of IL-6 and WBC were lower in patients who received intermittent therapy than those who received continuous therapy. Plasma IL-6 and IL-8 were increased when complicated with infection and IL-8 seemed more sensitive.
Conclusion: Plasma IL-6, sgpl30, IL-8 levels may reflect patients' responsiveness to ATRA treatment, and could be used to predict hyperleukocytosis and intercurrent infection. ATRA induces APL cell differentiation possibly via sgpl30 signal transducer chain. Measurement of sgp130 had certain meaning to prognosis.
